Crispr Therapeutics price target raised to $112 from $110 at Chardan

Chardan raised the firm’s price target on Crispr Therapeutics (CRSP) to $112 from $110 and keeps a Buy rating on the shares after its Q4 results and reaffirmed pipeline catalysts. CRSP now has 2 clinical stage in vivo editing assets: CTX310 targeting ANGPTL3 and CTX320 targeting Lp(a) – both in phase I trials after demonstrating dose dependent, durable hepatocyte editing and biomarker reductions in NHP studies last year, the analyst tells investors in a research note. The firm is positive that Crispr continues to benefit from two shots on goal, but Chardan is “slightly more cautious” on the CTX211 program after Vertex (VRTX) subsidiary ViaCyte’s decision to opt out of the collaboration.